Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions: I004, NovoLog; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
Interventions: Semi Quantitative Food Frequency Questionnaire (SQFFQ); Behavioral
Lead sponsor: San Raffaele University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 2,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2035
U.S. locations: 2
States / cities: Denver, Colorado • Chicago, Illinois

Conditions: Type 2 Diabetes Mellitus
Interventions: Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cough
Interventions: GSK5464714- Camlipixant; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Inflammatory Bowel Disease
Interventions: TD-1473, Itraconazole; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Prediabetes, Type 2 Diabetes
Interventions: Metformin, Liraglutide, Glargine, Placebo; Drug
Lead sponsor: RISE Study Group; Network
Eligibility: 20 Years to 65 Years
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington

Conditions: Healthy
Interventions: Terbinafine HCl 250mg tablets, Lamisil® 250 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obstructive Sleep Apnea
Interventions: Encore Tongue Suspension System; Device
Lead sponsor: Siesta Medical, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Gestational Diabetes
Interventions: Mobile health app called "Hola Bebe"; Behavioral
Lead sponsor: Environment and Health Group, Inc.; Industry
Eligibility: 19 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Maternal Obesity Syndrome
Interventions: cross-sectional; Other
Lead sponsor: University of Wyoming; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Laramie, Wyoming

Conditions: Diabetes Mellitus, Type 2
Interventions: Pioglitazone; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions: locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2; Biological · Drug
Lead sponsor: David Bartlett, MD; Other
Eligibility: 18 Years to 79 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: casopitant, dolasetron, granisetron, rosiglitazone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy
Interventions: Cefprozil for oral suspension 250 mg/5 mL, CEFZIL® for Oral Suspension 250 mg/5mL; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: Glucose, High Blood
Interventions: Human Insulin, Finger-actuated, Metered Pump Sprayer; Biological · Device
Lead sponsor: Transdermal Delivery Solutions Corp; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Palm Beach Gardens, Florida

Conditions: Healthy
Interventions: Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Parkinson Disease
Interventions: Smartshoes with haptic vibration feedback; Device
Lead sponsor: Stanford University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy
Interventions: Cilostazol 50 mg Tablets, Pletal®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Diabetes, Gestational
Interventions: 1-Self-monitoring of blood glucose, 2-Self-weighing, 3-Self-checking of blood pressure, 4-Checking fetal heart rate, 5-Visits with caregivers; Device · Procedure
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Healthy
Interventions: Sumatriptan Succinate Tablets 100 mg, Imitrex® Tablets 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Parkinson Disease
Interventions: rTMS; Device
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Herpes Zoster, Shingles, Genital Herpes
Interventions: Valacyclovir Hydrochloride; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Volunteers
Interventions: TAK-788, Itraconazole, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Calderasib OCT, Calderasib FCT; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

RISE Adult Medication Study

Terbinafine HCl 250 mg Tablet Under Fasting Conditions

FAST as a Treatment for Obstructive Sleep Apnea

Mobile Health App to Reduce Diabetes in Latina Women

Hormonal Regulation of Postpartum Weight and Presence of Gut Peptides in Human Milk

"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting

Dose Response Study of Transdermal Human Insulin in Patients

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

Smartshoes for Freezing of Gait in Parkinson's Disease

Cilostazol 50 mg Tablets Under Fasting Conditions

The Virtual Visit for Women With Gestational Diabetes

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-011)